Digital health technologies and machine learning augment patient reported outcomes to remotely characterise rheumatoid arthritis - Creagh, Andrew P.; Hamy, Valentin; Yuan, Hang; Mertes, Gert; Tomlinson, Ryan; Chen, Wen-Hung; Williams, Rachel; Llop, Christopher; Yee, Christopher; Duh, Mei Sheng; Doherty, Aiden; Garcia-Gancedo, Luis; et al. (medRxiv, 2023)
Digital measures of health status captured during daily life could greatly augment current in-clinic assessments for rheumatoid arthritis (RA), to enable better assessment of disease progression and impact. This work presents results from weaRAble-PRO, a 14-day observational study, which aimed to investigate how digital health technologies (DHT), such as smartphones and wearables, could augment patient reported outcomes (PRO) to determine RA status and severity in a study of 30 moderate-to-severe RA patients, compared to 30 matched healthy controls (HC). Sensor-based measures of health status, mobility, dexterity, fatigue, and other RA specific symptoms were extracted from daily iPhone guided tests (GT), as well as actigraphy and heart rate sensor data, which was passively recorded from patients’ Apple smartwatch continuously over the study duration. We subsequently developed a machine learning (ML) framework to distinguish RA status and to estimate RA severity. It was found that daily wearable sensor-outcomes robustly distinguished RA from HC participants (F1, 0.807). Furthermore, by day 7 of the study (half-way), a sufficient volume of data had been collected to reliably capture the characteristics of RA participants. In addition, we observed that the detection of RA severity levels could be improved by augmenting standard patient reported outcomes with sensor-based features (F1, 0.833) in comparison to using PRO assessments alone (F1, 0.759), and that the combination of modalities could reliability measure continuous RA severity, as determined by the clinician-assessed RAPID-3 score at baseline (r2, 0.692; RMSE, 1.33). The ability to measure the impact of disease during daily life—through objective and remote digital outcomes—paves the way forward to enable the development of more patient-centric and personalised measurements for use in RA clinical trials.Competing Interest StatementA.P.C, H.Y, G.M, A.D, D.A.C are employees of the University of Oxford. A.P.C is a GSK postdoctoral fellow and acknowledges the support of GSK. D.A.C received research funding from GSK to conduct this work. In addition, A.D., H.Y., and G.M. acknowledge the support of Novo Nordisk plc. A.D. AD is supported by the Wellcome Trust [223100/Z/21/Z]. V.H, W-H.C, R.T, R.W and L.G-G are employees of GSK and own stock and or shares. C.L, C.Y, M.S.D are employees of Analysis Group, which received research funding from GSK to conduct the study.Funding StatementThis study was funded by GSK plc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All documentation including the study protocol, any amendments, and informed consent procedures, were reviewed and approved by Reliant Medical Group's IRB. All participants provided written informed consent before any study procedures were undertaken. The study was conducted in accordance with the International Committee for Harmonisation principles of Good Clinical Practice and the Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymised individual participant data that support the findings of this study are available from the corresponding author, upon reasonable request and subject to GSK's approval.